Device Trial Radar · NCT04942834
Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
320
Actual
Start
Oct 1, 2021
Primary completion
Aug 23, 2025
Study completion Aug 23, 2025
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 29, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the effectiveness and safety of using cryoballoon ablation comparing with anti-arrhythmic drug therapy as initial treatment for naive patients with persistent atrial fibrillation.
Conditions
- Atrial Fibrillation, Persistent
- Arrhythmias, Cardiac
Interventions
Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and AmiodaroneDrug
Class I or III antiarrhythmic drug, including sotalol
cryoballoon ablationDevice
Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment success at 12 monthsTime frame: Randomization to 12 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Fujian Provincial Hospital
Fuzhou, Fujian, China
Dongguan People's Hospital
Dongguan, Guangdong, China
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.